Amid Uncertainties, Acorda Preps For Next Phase Of ACA: An Interview With Managed Markets Head Kent Rogers
With nine months to go before key aspects of the Affordable Care Act are implemented, Acorda Therapeutics’ head of managed markets, Kent Rogers, says he, like everyone, is ‘learning.” Acorda expects to have a game plan ready by mid-summer on how it will adapt its commercial strategy to ACA-initiated changes. Rogers also points out that the company may be less affected than others in the near term because Medicare already covers the majority of patients who take its multiple sclerosis drug Ampyra.
You may also be interested in...
New Insurance Marketplaces Won’t ‘Move The Needle’ Near-Term For Pharma Economics – An Interview With Booz & Co.
Jan. 1, 2014, the date insurance coverage expansion begins, is a key marker in the implementation of the Affordable Care Act, but experts, including Booz & Co. partners Elizabeth Powers and Greg Rotz say it isn’t likely to have a big near-term impact on drug manufacturers. Initial enrollment into health insurance exchanges and expanded Medicaid programs is expected to be limited, benefit plan designs are still unknown, and many uncertainties remain.
As manufacturers prepare comments on CMS’ proposed Medicaid pricing rule, areas of concern include the prohibition of “presumed inclusion” for drug sales to retail community pharmacies when calculating average manufacturer price, the definition of drug line extensions for rebate purposes, and definition of which drugs are “not generally dispensed through a retail community pharmacy.”
In a draft version of its annual instructions to Part D plans, CMS says it is seeking feedback from Part D sponsors and other stakeholders on “possible strategies for achieving better coordination” between stand-alone Medicare Part D plans and accountable care organizations to improve pharmacy care.